ABSTRACT
Predicting the future is always risky business. While an advanced understanding of the cellular basis of Graves’ orbitopathy holds great promise for a more rational therapeutic approach, often it is the unexpected development that fundamentally transforms the horizon. With this caveat, I will attempt to identify the more provocative recent reports and provide a view of the future, as flawed as it may prove to be.
